Frequently Asked Questions

What is the primary objective of a CSF viral shedding study?

The objective is to quantify the concentration of a viral vector (e.g., AAV) in cerebrospinal fluid following administration of a CNS-targeted gene therapy. This data is a regulatory expectation for IND-enabling toxicology studies and is used to assess vector biodistribution, persistence, and potential off-target exposure within the central nervous system.

Which assay platform is used for quantification?

Quantitative PCR (qPCR) is the standard platform for viral shedding analysis. We employ phase-appropriate, qualified, and validated qPCR assays under GxP guidelines to ensure data integrity and regulatory compliance for both preclinical and clinical programs. Digital droplet PCR (ddPCR)

Why are specific translational models chosen for CNS-targeted therapies?

For CNS-targeted therapies, certain translational models provide a vital bridge to human clinical outcomes. Selecting models with neuroanatomy and immune systems that closely mirror human biology is a requirement for generating predictive data. Analysis from these well-chosen models provides a more accurate assessment of potential vector distribution and persistence.

Proven Intelligence in Bioanalysis for Advanced Therapeutics

Applying decades of experience with proven success in bioanalysis is necessary for accelerating the development of advanced therapeutics and complex biologics. For gene therapies targeting the central nervous system, quantifying vector distribution in cerebrospinal fluid is a data-driven process that directly informs the safety profile and minimizes clinical risk ahead of regulatory submissions. A tailored preclinical strategy, supported by robust and sensitive assays, forms the basis of a successful IND filing.

The behavior of an AAV vector is dictated by its capsid. Engineering capsids to modulate tropism is a common strategy, yet this can introduce species-specific differences in glycan avidity and subsequent biodistribution patterns, as demonstrated in preclinical evaluations (PMID: 39001819). This variability requires analytical methods that are both sensitive and rigorously validated for the specific vector and biological matrix in question. Extrapolating data from one model or matrix to another without validation introduces unacceptable program risk.

Our approach to viral shedding analysis is built on this principle. We develop and qualify or validate qPCR assays specifically for challenging matrices like CSF, ensuring low limits of quantification and high precision.

Key components of our GxP-compliant CSF analysis include:

• Vector-Specific Assay Design: Primers and probes are designed to target unique sequences within the vector genome, ensuring specificity and avoiding detection of endogenous sequences.
• Phase-Appropriate Validation: Assays are qualified or validated according to GxP principles, meeting the stringent requirements for IND-enabling toxicology studies.
• Regulatory-Ready Reporting: Data is delivered in a format suitable for direct inclusion in IND and IMPD submissions, providing clear evidence of vector clearance or persistence.

By focusing on the unique bioanalytical requirements of CNS-targeted vectors like AAV9 and novel engineered capsids, we provide the definitive data needed to make informed decisions. This allows therapeutic developers to move forward with a clear understanding of their asset’s behavior in a clinically relevant context.

Return to Bioanalytical Services Hub